Joint research on CADASIL peptide drugs with the National Cerebral and Cardiovascular Center

「During the current consolidated fiscal year, we entered into exclusive license agreements with Himuka AM Pharma Co., Ltd. and the National Cerebral and Cardiovascular Center, respectively, concerning the development and commercialization of a CADASIL treatment using adrenomedullin, CADASIL being the English name.」

「During the current consolidated fiscal year, we began joint research with the National Cerebral and Cardiovascular Center aimed at developing a peptide pharmaceutical for CADASIL, a designated intractable disease. CADASIL, also known as CADASIL in English, causes serious symptoms such as cerebral infarction and dementia due to a mutation in a gene, but there is still no fundamental treatment. Together with the National Cerebral and Cardiovascular Center, we will promote the development of a treatment for CADASIL and contribute to people's health by delivering effective treatments to patients suffering from intractable diseases.」